SCHEMBL1314965

SCHEMBL1314965

C=C[Si](OCCCC)(c1ccccc1C)c1ccccc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.34
CYP2C9 P11712 6/20 0.33
CYP2C19 P33261 6/20 0.33
CYP19A1 P11511 5/20 0.33
CYP1A2 P05177 4/20 0.33
CYP2D6 P10635 3/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 3/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TLR8 Q9NR97 1/20 0.31
CCNB2 O95067 1/20 0.30
CCNE2 O96020 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1313756 0.84 MAPT (0.31) MAPT
SCHEMBL1318492 0.83 TSHR (0.31) TSHRL3MBTL1GAA
SCHEMBL1313341 0.82 LTA4H (0.39) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2
SCHEMBL15302212 0.81 GAA (0.42) CYP2C9L3MBTL1TDP1TLR8GAA
SCHEMBL1314716 0.80 TAAR1 (0.40) SMN1; SMN2ALDH1A1KDM4EMAPTKMT2A
SCHEMBL9402685 0.79 LTA4H (0.41) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2
SCHEMBL5549263 0.78 LTA4H (0.39) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2
SCHEMBL1312954 0.78 LTA4H (0.40) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2
SCHEMBL16892680 0.77 CYP19A1 (0.40) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2
SCHEMBL1315100 0.77 CYP2C9 (0.41) LTA4HCYP2C9CYP2C19CYP19A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163950-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-04-24 US disclosed
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2011-11-10 US disclosed
US-8008521-B2 Processes for the production of tri-organo-monoalkoxysilanes and process for the production of tri-organo-monochlorosilanes HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 2011-08-30 US disclosed
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES BANNOU TADASHI 2009-03-26 US disclosed
US-7459577-B2 Reacting a chlorosilane with grignard reagent SHIN-ETSU CHEMICAL CO., LTD. (JP) 2008-12-02 US disclosed
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes SHIN-ETSU CHEMICAL CO., LTD. (JP) 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275849-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X LTA4H 1128/4885CYP2C9 1132/4885CYP2C19 1865/4885
US-20090082585-A1 PROCESSES FOR THE PRODUCTION OF TRI-ORGANO-MONOALKOXYSILANES AND PROCESS FOR THE PRODUCTION OF TRI-ORGANO-MONOCHLOROSILANES MLX, HAX1, RPS4X LTA4H 1128/4885CYP2C9 1132/4885CYP2C19 1865/4885
US-20050070730-A1 Production processes for triorganomonoalkoxysilanes and triorganomonochlorosilanes MLX, HAX1, GRIA3 LTA4H 1556/4885CYP2C9 1279/4885CYP2C19 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.